Douglass Winthrop Advisors LLC Sells 100 Shares of Amgen Inc. (NASDAQ:AMGN)

Douglass Winthrop Advisors LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 0.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 14,140 shares of the medical research company’s stock after selling 100 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Amgen were worth $3,685,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Holderness Investments Co. increased its stake in shares of Amgen by 13.9% in the fourth quarter. Holderness Investments Co. now owns 7,626 shares of the medical research company’s stock worth $1,988,000 after purchasing an additional 928 shares in the last quarter. Blueshift Asset Management LLC purchased a new position in Amgen in the 4th quarter valued at approximately $345,000. Viawealth LLC raised its holdings in Amgen by 0.9% during the 4th quarter. Viawealth LLC now owns 7,594 shares of the medical research company’s stock valued at $1,979,000 after acquiring an additional 66 shares during the period. iA Global Asset Management Inc. lifted its position in shares of Amgen by 5.8% during the fourth quarter. iA Global Asset Management Inc. now owns 57,938 shares of the medical research company’s stock worth $15,101,000 after acquiring an additional 3,164 shares in the last quarter. Finally, Magnetar Financial LLC bought a new position in shares of Amgen in the fourth quarter worth $5,268,000. 76.50% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at $11,240,533.68. This represents a 40.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 in the last ninety days. Company insiders own 0.69% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of a number of analyst reports. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Royal Bank of Canada restated an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Johnson Rice set a $294.00 price objective on shares of Amgen in a research note on Wednesday, March 5th. Finally, Truist Financial lowered their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $314.04.

Amgen Trading Down 0.2 %

Shares of AMGN opened at $315.04 on Friday. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a market cap of $169.24 billion, a price-to-earnings ratio of 41.73, a PEG ratio of 2.63 and a beta of 0.53. The firm has a 50 day moving average price of $296.17 and a 200-day moving average price of $299.14. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.02%. Amgen’s payout ratio is 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.